2-吡咯烷-2-甲基-吡啶 | 524674-44-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-吡咯烷-2-甲基-吡啶
• 英文名称: 2-(Pyrrolidin-2-ylmethyl)pyridine
• CAS: 524674-44-0
• 化学式: C₁₀H₁₄N₂
• 分子量: 162.235
• InChiKey: HAPUOOBIEAPWAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-吡咯烷-2-甲基-吡啶 、 (S)-2-fluoro-6-(2-((1-hydroxy-3-phenylpropan-2-yl)amino)-2-oxoethoxy)benzoic acid 在 N,N-二异丙基乙胺 、 N,N'-羰基二咪唑 作用下， 以 N-甲基吡咯烷酮 为溶剂， 生成 2-[3-fluoro-2-[2-(pyridin-2-ylmethyl)pyrrolidine-1-carbonyl]phenoxy]-N-(1-hydroxy-3-phenylpropan-2-yl)acetamide
  参考文献：
  名称：

  Inhibitors of hepatitis C virus polymerase: Synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides

  摘要：

  SAR exploration from an initial hit, (S)-N-(2-cyclohexenylethyl)-2-fluoro-6-(2-(1-hydroxy-3-phenylpropan-2-ylamino)-2-oxoethoxy)benzamide (1), identified using our proprietary automated ligand identification system (ALIS),(1) has led to a novel series of selective hepatitis C virus (HCV) NS5B polymerase inhibitors with improved in vitro potency as exemplified by (S)-2-fluoro-6-(2-(1-hydroxy-3-phenylpropan-2-ylamino)-2-oxoethoxy)-N-isopentyl-N-methylbenzamidecarboxamide (41) (IC(50) = 0.5 mu M). The crystal structure of an analogue (44) was solved and provided rationalization of the SAR of this series, which binds in a distinct manner in the palm domain of NS5B, consistent with biochemical analysis using enzyme mutant variants. These data warrant further lead optimization efforts on this novel series of non-nucleoside inhibitors targeting the HCV polymerase. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.02.054

文献信息

• [EN] SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS<br/>[FR] TÉTRAHYDROAZOLOPYRAZINES SULFONYLÉES ET LEUR UTILISATION EN TANT QUE PRODUITS MÉDICAMENTEUX
  申请人：GRUENENTHAL GMBH

  公开号：WO2010099938A1

  公开（公告）日：2010-09-10

  The present invention relates to sulfonylated tetrahydroazolopyrazines, methods for the preparation thereof, medicinal products containing these compounds and the use of substituted indole compounds for the preparation of medicinal products (Formula I).

  本发明涉及磺酰化四氢咯啉吡嗪，其制备方法，含有这些化合物的药物产品以及用于制备药物产品的取代吲哚化合物的使用（式I）。
• BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Blaquiere Nicole

  公开号：US20110076291A1

  公开（公告）日：2011-03-31

  Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and where (i) X 1 is N and X 2 is S, (ii) X 1 is S and X 2 is N, (iii) X 1 is CR 7 and X 2 is S, (iv) X 1 is S and X 2 is CR 7 ; (v) X 1 is NR 8 and X 2 is N, (vi) X 1 is N and X 2 is NR 8 , (vii) X 1 is CR 7 and X 2 is O, (viii) X 1 is O and X 2 is CR 7 , (ix) X 1 is CR 7 and X 2 is C(R 7 ) 2 , (x) X 1 is C(R 7 ) 2 and X 2 is CR 7 ; (xi) X 1 is N and X 2 is O, or (xii) X 1 is O and X 2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  Formula I中的苯并氧杂环化合物，包括立体异构体、几何异构体、互变异构体、溶剂化合物、代谢物和其药学上可接受的盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；其中（i）X1为N且X2为S，（ii）X1为S且X2为N，（iii）X1为CR7且X2为S，（iv）X1为S且X2为CR7；（v）X1为NR8且X2为N，（vi）X1为N且X2为NR8，（vii）X1为CR7且X2为O，（viii）X1为O且X2为CR7，（ix）X1为CR7且X2为C(R7)2，（x）X1为C(R7)2且X2为CR7；（xi）X1为N且X2为O，或（xii）X1为O且X2为N，用于抑制脂质激酶，包括p110α和PI3K的其他同工酶，并用于治疗由脂质激酶介导的癌症等疾病。公开了利用Formula I中的化合物在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病或相关病理状况的方法。
• Substituted Pyrimidine and Triazine Compounds
  申请人：Schunk Stefan

  公开号：US20100173889A1

  公开（公告）日：2010-07-08

  Substituted pyrimidine and triazine compounds corresponding to formula I wherein R 1 , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b , R 7 , R 8 , R 9a , R 9b , R 10 , R 11 , A, a, b, s, t, V, W 1 , W 2 and W 3 have defined meanings, pharmaceutical compositions comprising such compounds, a process for preparing such compounds, and the use of such compounds and compositions to treat or inhibit pain and/or other disorders or disease states.

  将对应于公式I的嘧啶和三嗪化合物替代为R1、R2、R3、R4a、R4b、R5a、R5b、R7、R8、R9a、R9b、R10、R11、A、a、b、s、t、V、W1、W2和W3具有定义意义，包括这种化合物的药物组合物、制备这种化合物的过程，以及使用这种化合物和组合物来治疗或抑制疼痛和/或其他疾病状态的专利。
• PI3 KINASE INHIBITORS AND METHODS OF THEIR USE
  申请人：Ni Zhi-Jie

  公开号：US20100075965A1

  公开（公告）日：2010-03-25

  Phosphatidylinositol (PI) 3 kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, phospholipid kinases, G-protein coupled receptors, and phosphatases.

  磷脂酰肌醇（PI）3激酶抑制剂化合物及其药学上可接受的盐和前药；新化合物的组合物，可以单独使用或与至少一种其他治疗药物结合，与药学上可接受的载体；以及新化合物的用途，可以单独使用或与至少一种其他治疗药物结合，用于预防或治疗增殖性疾病，其特征是生长因子、蛋白质丝氨酸/苏氨酸激酶、磷脂酰肌醇激酶、G蛋白偶联受体和磷酸酶的异常活性。
• Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals
  申请人：MERLA Beatrix

  公开号：US20100234387A1

  公开（公告）日：2010-09-16

  Sulfonylated tetrahydroazolopyrazine compounds corresponding to the formula I wherein R 1 , R 2a , R 2b , R 3a , R 3b , R 4 , R 8 , R 9a , R 9b , R 10 , R 11 , A, B, W 1 , W 2 and W 3 have the meanings defined herein, pharmaceutical compositions containing such compounds, a method for the preparation of such compounds, and the use of such compounds for treating or inhibiting various types of pain and/or other conditions mediated at least in part by the bradykinin 1 receptor (B1R).

  公式I对应的是磺酰化四氢咪唑吡嗪化合物，其中R1、R2a、R2b、R3a、R3b、R4、R8、R9a、R9b、R10、R11、A、B、W1、W2和W3的含义如下所定义，该类化合物的制备方法、含有该类化合物的药物组合物以及利用该类化合物治疗或抑制至少部分由激肽1受体（B1R）介导的各种疼痛和/或其他疾病的用途。